Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Total Current Liabilities (2016 - 2023)

Rapid Therapeutic Science Laboratories' Total Current Liabilities history spans 8 years, with the latest figure at $4.4 million for Q2 2023.

  • For Q2 2023, Total Current Liabilities fell 8.95% year-over-year to $4.4 million; the TTM value through Jun 2023 reached $4.4 million, down 8.95%, while the annual FY2022 figure was $5.0 million, 62.65% up from the prior year.
  • Total Current Liabilities for Q2 2023 was $4.4 million at Rapid Therapeutic Science Laboratories, down from $4.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $5.1 million in Q1 2022 and bottomed at $128233.0 in Q1 2021.
  • The 5-year median for Total Current Liabilities is $1.5 million (2020), against an average of $2.4 million.
  • The largest annual shift saw Total Current Liabilities plummeted 91.42% in 2021 before it skyrocketed 3896.11% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $1.2 million in 2019, then fell by 0.56% to $1.2 million in 2020, then skyrocketed by 152.54% to $3.1 million in 2021, then soared by 62.65% to $5.0 million in 2022, then dropped by 10.88% to $4.4 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Total Current Liabilities are $4.4 million (Q2 2023), $4.5 million (Q1 2023), and $5.0 million (Q4 2022).